Compare NTLA & WWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | WWW |
|---|---|---|
| Founded | 2014 | 1883 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2016 | N/A |
| Metric | NTLA | WWW |
|---|---|---|
| Price | $13.82 | $17.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 9 |
| Target Price | $17.32 | ★ $23.25 |
| AVG Volume (30 Days) | ★ 6.5M | 1.8M |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | $57,528,000.00 | ★ $1,851,500,000.00 |
| Revenue This Year | $1.96 | $7.35 |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | ★ N/A | $16.02 |
| Revenue Growth | ★ 33.52 | 3.61 |
| 52 Week Low | $5.90 | $9.58 |
| 52 Week High | $28.25 | $32.80 |
| Indicator | NTLA | WWW |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 41.45 |
| Support Level | $13.86 | $16.80 |
| Resistance Level | $17.09 | $19.51 |
| Average True Range (ATR) | 1.28 | 0.88 |
| MACD | 0.29 | -0.19 |
| Stochastic Oscillator | 52.80 | 18.25 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.